Cargando…
Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
INTRODUCTION: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis. OBJECTIVES: This study aimed to evaluate the effectiveness, safety and survival of t...
Autores principales: | Di Brizzi, Eugenia Veronica, Buononato, Dario, Benvenuto, Pierfrancesco, Argenziano, Giuseppe, De Pasquale, Rocco, Fiorella, Carmen Silvia, Giofrè, Claudia, Musumeci, Maria Letizia, Palazzo, Giovanni, Zichichi, Leonardo, Balato, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656146/ https://www.ncbi.nlm.nih.gov/pubmed/37992389 http://dx.doi.org/10.5826/dpc.1304a215 |
Ejemplares similares
-
Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs
por: Di Brizzi, Eugenia Veronica, et al.
Publicado: (2022) -
Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis
por: Buononato, Dario, et al.
Publicado: (2022) -
Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022) -
Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019) -
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)